NEW YORK , Aug. 28, 2024 /PRNewswire/ -- Report with the AI impact on market trends- The global head and neck cancer diagnostics market size is estimated to grow by USD 6.30 billion from 2024-2028, according to Technavio.
The market is estimated to grow at a CAGR of 13.64% during the forecast period. Increasing incidences of head and neck cancers is driving market growth, with a trend towards rising use of immunotherapy in head and neck cancer treatment.
However, frequent product recalls poses a challenge. Key market players include AbbVie Inc., Accuray Inc.
, AdDent Inc., Bristol Myers Squibb Co., Canon Inc.
, Carestream Health Inc., Eli Lilly and Co., Esaote Spa, Flexicare Group Ltd.
, General Electric Co., Hitachi Ltd., KARL STORZ SE and Co.
KG, Koninklijke Philips N.V., Merck KGaA, Olympus Corp.
, Optim LLC, Shimadzu Corp., Siemens AG, Sumitomo Mitsui Financial Group, and Xoran Technologies LLC. Get a detailed analysis on regions, market segments, customer landscape, and companies- View the snapshot of this report Market Driver Immunotherapy, a form of cancer treatment also known as biological therapy, is strengthening the body's natural defenses against head and neck cancer.
Approved immunotherapies for head and neck cancer treatment include immune checkpoint inhibitors. These drugs, such as pembrolizumab (Keytruda) and nivolumab (Opdivo), trigger the immune system to destroy cancer cells. The FDA has approved these medications for persons with recurrent or metastatic head a.